Ottawa, Ontario
- (Marketwired – August 29, 2017) – Tetra
Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today
announced that it has strengthened its management team in preparation for the
initiation of its commercial activities with the appointments of Dr.
Anne-Sophie Courtois to the position of Vice President, Marketing effective
immediately and Mr. Bernard Lessard to the position of Chief Financial Officer
(CFO), effective September 18, 2017. Mr.
Lessard will be replacing Mr. Sabino Di Paola as CFO of the corporation.
“I
am very proud and pleased to be able to count on Dr. Courtois and Mr. Lessard
as members of our executive team,” said Bernard Fortier, CEO of Tetra
Bio-Pharma. “They will be playing a key role as Tetra imminently initiates its
commercial activities and generates revenues in 2017. These highly skilled and
experienced individuals will further strengthen our organization as we execute
our strategy and refine the tactics that will position Tetra as a
biopharmaceutical leader in cannabinoid-based drug discovery, with a clinical
program aimed at bringing novel drugs and treatments to patients and their
healthcare providers.”
About
Anne-Sophie Courtois, DVM:
Dr.
Courtois has been working in the pharmaceutical industry for over 10 years in
Europe and North America. She held the
role as Director of Marketing and Scientific Affairs at Jamp Pharma (generic
division) and Orimed Pharma (medical division) for over 4 years where she
successfully led the marketing team to a 150% growth in sales while preparing
the strategic plans for the medical and generic divisions. She managed the marketing of the fastest
growing Canadian generic company which launched over 120 products in that
time. In addition, she managed the
marketing of the medical division, successfully launching over 10 branded
products, prescription and OTC under medical recommendation, in a wide
diversity of therapeutic areas (osteoporosis, sexual dysfunction, pain management
and vitamin deficiency). She has
international experience managing product lines and scientific and commercial
training of multiple sales teams across Canada, USA and Europe in retail with
natural health products, generics and prescription brands. Dr. Courtois has been very effective in
launching products faster and efficiently as a member of the operations
go-to-market team. Her core expertise is
building brands with a strong identity that have a credible scientific
background while fulfilling an unmet need on the market for patients and health
care professionals. Dr. Courtois is a
veterinary doctor and holds a Specialized Masters in management and
entrepreneurship from HEC Paris.
About
Bernard Lessard, MBA, CPA, CMA:
Mr. Lessard has considerable experience as an
executive in the life sciences sector serving as a member of the c-suite and as
a trusted advisor to the board of directors in managing business strategy and
research teams. He has been involved in
numerous financings and the establishment of venture capital funds for start up
companies in Quebec, dedicated to the life sciences sector. Mr. Lessard launched a new biotech start-up
as CEO of the organization. Mr. Lessard
has held the role of portfolio manager in helping companies finance their
future growth and as a special project director to implement business
turnarounds. He has considerable
experience as a CFO in risk management and he has successfully managed the
mergers and acquisitions process of various companies while enhancing the
assets of these organizations. Mr.
Lessard has considerable political connections with the Quebec government where
he has served as a policy advisor with various Quebec government ministers with
a specific mandate involving intellectual property and venture capital as a
market strategy for the life sciences sector.
He is actively involved in the business community with an extensive
network both in the public and private sectors.
Mr. Lessard is a member of the Quebec Order of Chartered Professional
Accountants - CPA (Ordre des comptables agréés du Québec) and is a Certified
Management Accountant - CMA. He has a Masters in Business Administration and
has a very strong interest in corporate governance.
Corporate Update:
The Corporation would like to thank Mr. Di Paola for all
his efforts in working to grow Tetra where it is today and wish him all the
best in his future endeavours.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a
biopharmaceutical leader in cannabinoid-based drug discovery and development with
a clinical program aimed at bringing novel drugs and treatments to patients and
their healthcare providers. The Company
has several subsidiaries that are engaged in the development of Bio
Pharmaceuticals and Natural Health Products containing Cannabis and other
medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the
traditional methods of medicinal cannabis use with the supporting scientific validation
and safety data required for inclusion into the existing bio pharma industry by
regulators, physicians and insurance companies.
More information is available about the company at: www.tetrabiopharma.com.
Source: Tetra Bio-Pharma
For further information, please contact Tetra
Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(514) 360-8040 Ext. 203
Neither
the TSX Venture Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-looking
statements
Some
statements in this release may contain forward-looking information. All statements, other than of historical
fact, that address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future (including,
without limitation, statements regarding potential acquisitions and financings)
are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words "may", "will", "should",
"continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan"
or "project" or the negative of these words or other variations on
these words or comparable terminology.
Forward-looking statements are subject to a number of risks and uncertainties,
many of which are beyond the Company's ability to control or predict, that may
cause the actual results of the Company to differ materially from those
discussed in the forward-looking statements.
Factors that could cause actual results or events to differ materially
from current expectations include, among other things, without limitation, the
inability of the Company, through its wholly-owned subsidiary, GrowPros MMP
Inc., to obtain a licence for the production of medical marijuana; failure to obtain
sufficient financing to execute the Company’s business plan; competition;
regulation and anticipated and unanticipated costs and delays, and other risks
disclosed in the Company's public disclosure record on file with the relevant
securities regulatory authorities.
Although the Company has attempted to identify important factors that
could cause actual results or events to differ materially from those described
in forward-looking statements, there may be other factors that cause results or
events not to be as anticipated, estimated or intended. Readers should not place undue reliance on
forward-looking statements. The
forward-looking statements included in this news release are made as of the
date of this news release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable securities
legislation.